Professor Kaye Williams BSc PhD FSB
Professor; Group Leader Hypoxia and Therapeutics
- Email: email@example.com
- Telephone: +44 (0)161 275 2428
- Alternative Telephone: +44 (0)161 275 2358 (Lesley Wright (PA))
- Fax: 0161 275 8349
University of Manchester
Manchester Pharmacy School
Room 3.126, Stopford Building
Manchester M13 9PT
Outside of running a successful research group and teaching highly motivated students on the MPharm programme, my academic leadership and management roles within the University of Manchester are focused upon the promotion and development of research. Specific contributions are made via roles in the following groups:
- Pre-clinical lead for oncology imaging within the Manchester Cancer Research Centre. To establish, direct and implement the pre-clinical non-invasive imaging strategy within the MCRC. Leadership has resulted in procurement of new preclinical PET/CT scanner, development of strategic research interaction within imaging science with industrial partners (for example GE, AstraZeneca, Lilly) and kick-started oncology-based projects within MCRC across different research areas.
- MAHSC Experimental Medicine Strategy Board
- Chair of the Manchester Pharmacy School Board
- Member of the Athena Swan Self-assessment Team
- Deputy Research Director Pharmaceutical Sciences, Manchester Pharmacy School, 2013
Memberships of Committees and Professional Bodies
- Research Council of Norway; Panel Reviewer: Independent Projects in Medicine, Health Sciences and Biology (FRIMEDBIO) 2012-
- Member of the Scientific Advisory Board for the Breast Cancer Campaign 2011-
- Councillor for the International Association for Radiation Research 2011-
- Past Chair of the Association for Radiation Research 2012-2014
- Co-Chair Basic Science Workstream; National Cancer Research Institute (NCRI) Clinical and Translational Radiotherapy Research (CTRad) Working Group 2010-2014
- Member of the NCRI CTRad Executive Group 2010-
- Fellow of the Society of Biology 2010-
- Trustee of the LH Gray Memorial Trust (2006-). Current secretary and treasurer.
- British Association for Cancer Research
- European Association for Cancer Research
- American Association for Cancer Research
- Association of Radiation Research
- Radiation Research Society
- British Institute of Radiology
Kaye currently leads an integrated and multi-disciplinary team whose overall goal is to exploit tumour hypoxia and the factors that govern cellular response to this tumour specific micro- environmental stress for therapeutic benefit. Specific avenues of Kaye’s research have focussed upon the contribution of the transcription factor hypoxia inducible factor-1 (HIF-1) to tumour growth and response to therapy both in vitro and in vivo. Novel findings from these studies have highlighted HIF-1 as a key target for anti-cancer therapeutic design and in particular have provided a rationale for the application of HIF-1 targeted therapies in combination with conventional chemo and/or radiotherapy. In addition to using HIF-1 targeted approaches Kaye also has a keen interest in the use of other molecular targeted therapies in combination with radiation treatment. In particular she has investigated the impact of novel agents on the underlying mechanisms that govern radiation response to enable their optimal application in a clinical radiotherapy context. These studies have underpinned ongoing clinical trials within The Christie, Manchester, that are showing positive patient benefit. Recently, Kaye has taken a lead role in the development of pre-clinical imaging for oncology applications within the Manchester Cancer Research Centre. The focus here is to develop, validate and apply image derived biomarkers to assess changes in tumour biology and therapeutic response. Kaye played a key role in the recent successful application to develop an EPSRC/CRUK funded Comprehensive Cancer Imaging Centre between the Universities of Manchester and Cambridge.
Patents filed and approved
- Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor. 05801173.5-2123-IB2005002900, filed Sept 2005
- Carbonic anhydrase inhibitors. PCT/EP2011/052156, filed Feb 2011
If you would like to apply for a PhD under the supervision of Professor Williams, please visit this page.
- Year 4. Cancer Biology and Therapy
- Academic Advisor : 26 Advisees Years 1-4
- Fourth year MPharm Research Project Supervisor
External Teaching and Assessment:
- Biological Basis of Cancer Therapy Course (Royal College accredited Training Course for Clinical and Medical Oncology Specialist Registrars covering Fellowship of the Royal College of Radiology part 1 examination syllabus), Christie Hospital NHS Trust, Manchester. 2005- to date
- MSc Oncology, Tumour Physiology Module, University of Nottingham. Teaching lecture “Tumour Hypoxia”. 2005- to date
- MSc Oncology, Radiation Sciences for the Clinical and Medical Oncologist, The Institute of Cancer Research, London. Teaching lecture “Hypoxia and Radiation”; 2009- to date
- MSc Radiation Biology, University of Oxford, teaching lectures in hypoxia and radiobiology; 2010- to date
- Specialist examiner [Cancer Biology] Fellowship of the Royal College of Radiologist examinations 2010-
- External examiner MSc Cancer Pharmacology, University of Bradford 2011-
- External examiner MPharm, Queen’s University Belfast 2012-2016
• Member of the examining board for the first FRCR examination in Clinical Oncology
Professor Kaye Williams is the Leader of the Hypoxia and Therapeutics Group within the Manchester Pharmacy School. Kaye joined the Experimental Oncology division in November 1996 upon completion of PhD studies. Following back-to-back Research Associate and Research Fellow positions funded by the Medical Research Council, she gained a tenured Senior Lecturer position in January 2006, was promoted to Reader in July 2010 and Chair in Experimental Therapeutics and Imaging in August 2012. Her group currently focuses upon the tumour microenvironment, investigating therapeutic targets, vascular biology and molecular interactions. She also leads pre-clinical imaging development within the Manchester Cancer Research Centre. Her research is funded via the MRC, BBSRC, EPSRC, Cancer Research UK and the European Union, with commercial funding via collaboration with a number of Pharmaceutical Companies.
Kaye was awarded the British Association for Cancer Research/AstraZeneca Frank Rose Young Scientist Award in 2005, and was elected a Fellow of the Society of Biology in 2010.
- 1997 - PhD Faculty of Medicine - University of Manchester
- 1993 - BSc (Hons) Molecular Biology - First Class, School of Biological Sciences, University of Manchester
Collaborators and affiliated staff
Dr Roben Gieling - Post-doctoral Researcher
Dr Katie Finegan - Post-doctoral Researcher
Dr Duncan Forster- Post-doctoral Researcher
Mrs Alison Smigova- Lab manager, Preclinical PET Imaging
Mr Muhammad Babur- Research Technician
Mr Brian Telfer- Experimental Officer
Ms Kathryn Blount- PhD student
Ms Fiona Henderson- PhD student
Ms Jennifer Bryant- PhD student
Dr Ibrahim Djoukhadar- Clinical Research Fellow
Dr Costas Demonacos - Molecular Pharmacology, redox sensitive transcriptional regulation
Professor Caroline Dive - Mechanisms of hypoxia-mediated modification of chemotherapy response
Professor Ian Stratford - Tumour biology
Professor Anne White - Endocrine tumour biology
Professor Roy Goodacre - Metabolomics
Dr Adam McMahon - Integration of imaging and proteomic tools; PET radiochemistry
Dr James O’Conno r- MR imaging
Dr Jason Bruce - Pancreatic Cancer
Mehibel M, Singh S, Cowen RL, Williams KJ, Stratford IJ. (2016).
Meredith SL, Bryant JL, Babur M, Riddell PW, Behrouzi R, Williams KJ, White A. (2016).
Armitage EG, Kotze HL, Allwood JW, Dunn WB, Goodacre R, Williams KJ. (2015).
Metabolic profiling reveals potential metabolic markers associated with Hypoxia Inducible Factor-mediated signalling in hypoxic cancer cells. Sci Rep, 5(15649), 1-12. eScholarID:277601 | DOI:doi: 10.1038/srep15649
Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, Domarkas J, Lord S, Baldry C, Gilbert FJ. (2015).
McCrudden CM,O'Rourke MG, Cherry KE, Yuen HF, O'Rourke D, Babur M, Telfer BA, Thomas HD, Keane P, Nambirajan T, Hagan C, O'Sullivan JM, Shaw C, Williams KJ, Curtin NJ, Hirst DG, Robson T. (2015).
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself. PLoS One, 10(2), e0118187. eScholarID:264295 | DOI:doi: 10.1371/journal.pone.0118187
Roben Gieling, Richard Fitzmaurice, Brian Telfer, Muhammad Babur, Kaye J Williams. (2015).
Dissemination via the lymphatic or angiogemnic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases. Clin Exp Metastasis, 32(6), 567-577. eScholarID:269268 | DOI:10.1007/s10585-015-9728-z
Cian M. McCrudden and Kaye J. Williams. (2014).
The vasoactivity of PARP inhibitors. In eds Professor Nicola Curtin and Dr Ricky Sharma (Ed.), In PARP Inhibitors for Cancer Therapy. Published by Springer, under the series Cancer Drug Discovery and Development, managed by Series Editor, Dr. Beverly Teicher (Chief, Molecular Pharmacology Branch, National Cancer Institute). eScholarID:239833
Emily G Armitage, Helen L Kotze, Kaye J Williams. (2014).
Correlation-based network analysis of cancer metabolism- A new systems biology approach in metabolomics. In 2014 ISSN 2193-4746 DOI 10.1007/978-1-4939-0615-4 (Ed.), Springerbriefs in systems biology. London: Published by Springer New York Heidelberg Dordrecht. eScholarID:239836
An Wouters, Bea Pauwels, Natalie Burrows, Marc Baay, Vanessa Deschoolmeester, Trung N Vu, Kris Laukens, Paul Meijnders, Dirk Van Gestel, Kaye J Williams, Danielle Van den Weyngaert, Jan B Vermorken, Patrick Pauwels, Marc Peeters and Filip Lardon. (2014).
The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein. BMC Cancer, eScholarID:239826 | DOI:10.1186/1471-2407-14-594
Becky M Bola, Amy L Chadwick, Filippos Michopoulos, Kathryn G Blount, Brian A Telfer, Kaye J. Williams, Paul Smith, Susan D Critchlow, Ian J Stratford. (2014).
Inhibition of Monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther, eScholarID:239830
Kadirvel M, Fairclough M, Cawthorne C, Rowling EJ, Babur M, Birkett P, Smigova A, McMahon A, Freeman S, Birkket P, Williams KJ and Brown G. (2014).
Detection of apoptosis by PET/CT with the diethyl ester of [18F]ML-10 and fluorescence imaging with a dansyl analogue. Bioorg Med Chem, 22(1), 341-349. eScholarID:217736 | DOI:10.1016/j.bmc.2013.11.019
Paul Bassan, Joe Mellorb, Jonathan Shapiro, Kaye J Williams, Michael Lisanti and Peter Gardner. (2014).
Cawthorne C, Burrows N, Gieling RG, Morrow C, Forster D, Gregory J, Smigova A, Babur M, Hodgkinson C, Dive C, Wilson I, Williams KJ. (2013).
[18F]-FLT Positron Emission Tomography can be used to image the response of sensitive tumors to PI3-Kinase inhibition with the novel agent GDC-0941. Mol Cancer Therapeutics, eScholarID:188376
Kotze HL, Armitage EG, Fletcher JS, Henderson A, Williams KJ, Lockyer NP, Vickerman JC. (2013).
ToF-SIMS as a tool for metabolic profiling small biomolecules in cancer systems. Surface Interface Analysis, 45, 277-281. eScholarID:188378
- Natalie Burrows, Brian Telfer, Georg Brabant, Kaye J. Williams. (In-press). Inhibiting the phosphatidylinositide 3-kinase pathway blocks radiation-induced metastasis associated with Rho-GTPase and Hypoxia-inducible factor-1 activity. Radiotherapy and Oncology - dx.doi.org/10.1016/j.radonc.2013.06.027, eScholarID:211095
Simpson KL, Cawthorne C, Zhou C, Hodgkinson CL, Walker MJ, Trapani F, Kadirvel M, Brown G, Dawson MJ, MacFarlane M, Williams KJ, Whetton AD, Dive C. (2013).
A caspase-3 ‘death-switch’ in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers. Cell Death and Disease, 4, e613. eScholarID:188364 | DOI:10.1038/cddis.2013.137
- Stovold R, Meredith SL, Bryant JL, Babur M, Williams KJ, Dean EJ, Dive C, Blackhall FH, White A. (In-press). Neuroendocrine and epithelial phenotypes in small cell lung cancer: implications for metastasis and survival in patients. British Journal of Cancer, eScholarID:188365
Ferreras C, Rushton G, Cole CL, Babur M, Telfer BA, van Kuppevelt TH, Gardiner JM, Williams KJ, Jayson GC, Avizienyte E. (2012).
Endothelial Heparan Sulfate 6-O-sulfation Levels Regulate Angiogenic Responses of Endothelial Cells to FGF2 and VEGF. J Biol Chem, 287(43), 36132-46. eScholarID:176430
Gieling RG, Babur M, Mamnani L, Burrows N, Telfer BA, Carta F, Winum J-Y, Scozzafava A, Supuran CT Williams KJ. (2012).
1. Natalie Burrows, Muhammad Babur, Julia Resch, Sophie Ridsdale, Melissa Mejin, Georg Brabant and Kaye J Williams. (2011).
GDC-0941 Inhibits Metastatic Characteristics of Thyroid Carcinomas by Targeting both the Phosphoinositide-3 Kinase (PI3K) and Hypoxia-Inducible Factor-1α (HIF-1α) Pathways. The Journal of Clinical Endocrinology & Metabolism, 96(12), e1934-1943. eScholarID:140736 | DOI:10.1210/jc.2011-1426
4. Monika Golinska, Helen Troy, Yuen-Li Chung, Paul MJ McSheehy, Manuel Mayr, Xiaoke Yin, Lucy Ly, Kaye J Williams, Rachel Airley, Adrian L Harris, John Latigo, Meg Perumal, Eric Aboagye, David Perrett, Marion Stubbs and John R Griffiths. (2011).
Majid Ali, Marzieh Kamjoo, Huw D Thomas, Suzanne Kyle, Ivanda Pavlovska, Muhammed Babur, Brian A Telfer, Nicola J Curtin and Kaye J Williams. (2011).
The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but doesn’t enhance the efficacy of doxorubicin, despite improving tumour perfusion and radiation response in mice. Mol Cancer Therapeutics, 10(12), 2320-2329. eScholarID:140738 | DOI:10.1158/1535-7163.MCT-11-0356
Burrows N, Resch J, Cowen RL, von Wasielewski R, Hoang-Vu C, West CM, Williams KJ, Brabant G. (2010).
Lunt, S., Cawthorne, C., Ali, M., Telfer, B., Babur, M., Smigova, A., Julyan, P., Price, P., Stratford, I., Bloomer, W., Papadopoulou, M. & Williams, K (2010).
The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy. Br J Cancer, 103, 201-208. eScholarID:86071 | PMID:20588272 | DOI:10.1038/sj.bjc.6605753
Sommer P, Cowen RL, Berry A, Cookson A, Telfer BA, Williams KJ, Stratford IJ, Kaye P, White A, Ray DW. (2010).
Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumour growth. Endocrine-Related Cancer, 17, 203-213. eScholarID:76836 | DOI:10.1677/ERC-09-0241
3. Williams KJ*, Albertella MR*, Fitzpatrick B, Loadman PM, Shnyder SD, Chinje EC, Telfer BA, Dunk CR, Harris PA and Stratford IJ. (2009).
Ali, M., Telfer, B., McCrudden, C., O'Rourke, M., Thomas, H., Kamjoo, M., Kyle, S., Robson, T., Shaw, C., Hirst, D., Curtin, N. & Williams, K (2009).
Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo? Clinical cancer research, 15(19), 6106. eScholarID:74292 | PMID:19789326 | DOI:10.1158/1078-0432.CCR-09-0398
Shannon AM, Telfer BA, Smith PD, Babur M, Logie A, Wilkinson RW, Debray C, Stratford IJ, Williams KJ* and Wedge SR. (2009).
The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts. Clinical Cancer Research, 15(21), 6619-6629. eScholarID:78745 | DOI:10.1158/1078-0432.CCR-08-2958